[{"id":"ad50b74e-df77-4142-938b-467110fb4a75","acronym":"SYMPHONY-1","url":"https://clinicaltrials.gov/study/NCT04224493","created_at":"2023-06-02T17:05:31.313Z","updated_at":"2024-07-02T16:34:26.311Z","phase":"Phase 3","brief_title":"Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04224493 - SYMPHONY-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 612","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"},{"id":"2bbb09d4-a4c2-44c0-86f9-0f0a553fad4d","acronym":"Mandolin","url":"https://clinicaltrials.gov/study/NCT06068881","created_at":"2023-10-05T16:11:20.119Z","updated_at":"2024-07-02T16:34:59.499Z","phase":"Phase 2","brief_title":"A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an \"EZH2 Gain-of-function\" Genetic Mutation","source_id_and_acronym":"NCT06068881 - Mandolin","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/02/2024","start_date":" 09/02/2024","primary_txt":" Primary completion: 09/28/2027","primary_completion_date":" 09/28/2027","study_txt":" Completion: 09/28/2027","study_completion_date":" 09/28/2027","last_update_posted":"2024-06-03"},{"id":"d5547275-acd2-4edc-8fac-11affa680d28","acronym":"CELLO-1","url":"https://clinicaltrials.gov/study/NCT04179864","created_at":"2021-01-18T20:22:59.772Z","updated_at":"2024-07-02T16:34:59.510Z","phase":"Phase 1/2","brief_title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","source_id_and_acronym":"NCT04179864 - CELLO-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":"","alterations":" ","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tazverik (tazemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-06-03"},{"id":"e4a4b657-550e-4739-b71c-fff75613dfbe","acronym":"ETCTN 10500","url":"https://clinicaltrials.gov/study/NCT05627245","created_at":"2022-11-25T15:58:14.707Z","updated_at":"2024-07-02T16:35:09.644Z","phase":"Phase 1","brief_title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","source_id_and_acronym":"NCT05627245 - ETCTN 10500","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EZH2","pipe":" | ","alterations":" RAS wild-type • EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-15"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"2f5faace-17d7-4cff-b721-8014409cdd5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05811546","created_at":"2023-04-13T14:03:16.109Z","updated_at":"2024-07-02T16:35:50.662Z","phase":"","brief_title":"Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma","source_id_and_acronym":"NCT05811546","lead_sponsor":"Assiut University","biomarkers":" EZH2 • DNMT1","pipe":"","alterations":" ","tags":["EZH2 • DNMT1"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-04-13"},{"id":"e3639bdd-08ec-4697-b607-8bdfa56d08c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04215822","created_at":"2021-02-26T09:55:08.488Z","updated_at":"2024-07-02T16:36:51.906Z","phase":"","brief_title":"PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia","source_id_and_acronym":"NCT04215822","lead_sponsor":"Assiut University","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 deletion","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 deletion"],"overall_status":"Unknown status","enrollment":" Enrollment 80","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/30/2022","primary_completion_date":" 01/30/2022","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2020-01-03"}]